Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
By T. Wilson, Jane Fridlyand, Yibing Yan, E. Penuel, L. Burton, E. Chan, Jing Peng, Eva Lin, Yulei N. Wang, J. Sosman and 8 more. Nature, 2012
1,147 citations recorded by the source corpus.
Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-‘addicted’ human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.
Subfields: Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/13c393db70238530c2d20d136288e6af04b32c16
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pathology and Forensic Medicine
Citations in the corpus
- Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Kinase inhibition triggers a strong discerning pressure for cells to acquire resistance to chemotherapy through kinase mutations [263].”
- New horizons in tumor microenvironment biology: challenges and opportunities (2015, background): “Tumors employ various strategies to recruit MSCs and chemokines are the most reported; for instance, breast tumors secret monocyte chemotactic protein-1 to stimulate the migration of MSCs, while prostate tumors release CXCL16 to attract MSCs via binding to the CXCR receptor on these cells [43,61].”
- Fibroblast heterogeneity in the cancer wound (2014, background): “…MTC4 expression (a functional marker of hypoxia, oxidative stress, aerobic glycolysis, and lactate efflux) was shown to be correlated with decreased overall survival in triple-negative breast cancer, whereas expression of MTC4 in neoplastic cells had no prognostic value (Witkiewicz et al., 2012).”
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016, positive): “The gene targets covered by this assay are as follows (exons): AKT1 (3), ALK (22, 23, 25), APC (16), BRAF (11, 15), CDH1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16), CDKN2A (1, 2, 3), CTNNB1 (3), DDR2 (12, 13, 14, 15, 16, 17, 18), EGFR (7, 15, 18, 19, 20, 21), ERBB2 (10, 20), ESR1 (8), FB”
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine (2017, background): “For example, resistance to small-molecule RAF inhibitors is conferred by tumor-associated fibroblasts that secrete hepatocyte growth factor (HGF) (5, 6).”
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (2013, positive): “Furthermore, in agreement with recent studies (29, 46, 47), we found that HGF stimulation is sufficient to confer cetuximab and panitumumab resistance both in vitro and in vivo.”
- Glucocorticoid Receptor Confers Resistance to Anti-Androgens by Bypassing Androgen Receptor Blockade (2013, positive): “…bypass model of AR pathway blockade reported here is reminiscent of recent reports that kinase inhibitor blockade in various cancers can be overcome by upregulation of other kinases and/or their ligands (Engelman et al., 2007; Johannessen et al., 2010; Straussman et al., 2012; Wilson et al., 2012).”